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Abstract
Background: Quinine (QN) remains the first line anti-malarial drug for the treatment of complicated malaria in Europe 
and Africa. The emergence of QN resistance has been documented. QN resistance is not yet a significant problem, but 
there is an urgent need to discover partners for use in combination with QN. The aim of the study was to assess the in 
vitro potentiating effects of atorvastatin (AVA), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitor, in combination with QN against Plasmodium falciparum and to evaluate whether the effects of AVA could be 
associated with gene copy number or mutations in genes involved in QN resistance, such as pfcrt, pfmdr1, pfmrp and 
pfnhe.
Methods: The susceptibilities to combination of AVA with QN were assessed against 21 parasite strains using the in 
vitro isotopic microtest. Genotypes and gene copy number were assessed for pfcrt, pfmdr1, pfmdr2, pfmrp genes. In 
addition, the number of DNNND, DDNHNDNHNN repeats in pfnhe-1 ms4760 and the ms4760 profile were determined 
for each strains of P. falciparum.
Results: AVA demonstrated synergistic effects in combination with QN against 21 P. falciparum strains. The QN IC50 was 
reduced by 5% (0% to 15%; 95%CI: 1%-8%), 10% (3% to 23%; 95%CI: 7%-14%) and 22% (14% to 40%; 95%CI: 19%-25%) 
in presence of AVA at concentrations of 0.1, 0.5 and 1.0 μM, respectively. These reductions were all significant (p < 
0.009). The reduction in the QN IC50 in presence of AVA was not significantly correlated with the QN IC50 (r = 0.22, P = 
0.3288) or the AVA IC50 (r = 0.03, P = 0.8946). The synergistic effect of AVA in combination with QN was not significantly 
associated with polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 genes that could be involved in QN resistance. 
The synergistic effect of AVA on QN responses was not significantly associated with pfmdr1 copy number (P = 0.0428).
Conclusion: The synergistic effect of AVA in combination with QN was found to be unrelated to mutations occurring in 
transport protein genes involved in QN drug resistance. The different mechanisms of drug uptake and/or mode of 
action for AVA compared to the other anti-malarial drugs, as well as the AVA-mediated synergy of the anti-malarial 
effect of QN, suggests that AVA will be a good candidate for combinatorial malaria treatment. All of these observations 
support calls for both an in vivo evaluation with pharmacokinetic component and clinical trials of AVA as an anti-
malarial therapy.
Background
During the past 20 years, many strains of Plasmodium
falciparum  have become resistant to chloroquine and
other anti-malarial drugs [1]. This has prompted a search
for an effective alternative anti-malarial drug with mini-
mal side effects. The emergence and spread of parasites
resistant to anti-malarial drugs has resulted in an urgent
need for discovery and development of novel anti-malar-
ial compounds.
Quinine (QN) has been used as a malaria treatment for
more than 350 years in Africa and remains the first-line
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anti-malarial drug for the treatment of complicated
malaria in Europe and Africa. However, cases of QN clin-
ical failure were observed in Brazil and Asia in the 1960s
[2,3]. In the 1980s, clinical failures became more frequent
in Southeast Asia, South America and Africa [4-8]. How-
ever, QN resistance is not yet a significant problem. QN
continues to be widely used at present as a second-line
therapy for uncomplicated malaria in Africa and other
areas. Nevertheless, there is an urgent need for discovery
partners for combination with QN.
Atorvastatin (AVA), a 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitor, belongs to
a family of lipid-lowering drugs that are currently used
for the control of hyperlipidaemia and are considered
useful for protection from cardiovascular events. Apart
from the cholesterol-lowering activity of statins, the
immunomodulatory and pleiotropic effects of statins may
significantly impact infection-related survival [9,10]. AVA
reduced the intracellular growth of Salmonella typhimu-
rium in macrophages in a mouse model [11]. Addition-
ally, AVA has an anti-hepatitis C virus (HCV) effect and
enhanced the anti-HCV effect of interferon when used in
combination [12]. However, the use of statin alone in
patients with, or at risk of, severe infections is conten-
tious [13]. Preoperative statin use was not associated with
a reduction of the rate of postoperative infection among
patients who underwent cardiac surgery.
Statins severely interfered with the growth of protozoan
parasites in the Trypanosomatidae family, such as Try-
panosoma cruzi and various Leishmania species [14-16].
Additionally, an HMG-CoA reductase has been detected
in Trypanosoma and Leishmania [16].
AVA demonstrated anti-malarial activity in vitro even
though an HMG-CoA homolog was not identified by
BLASTX analysis of the P. falciparum sequence with
other protozoal HMG-CoA protein sequences [17]. AVA
is ten-fold more active against P. falciparum strains than
other statins [17]. Additionally, AVA demonstrated no in
vitro cross-resistance with quinine, chloroquine,
monodesethylamodiaquine, mefloquine, lumefantrine,
dihydroartemisinin, atovaquone, or doxycycline, and the
IC50 values for AVA were found to be unrelated to muta-
tions in transport protein genes involved in quinoline
anti-malarial drug resistance, such as pfcrt,  pfmdr1,
pfmrp, and pfnhe-1 [18]. AVA had synergistic effects in
combination with dihydroartemisinin [19].
AVA is also an inhibitor of phosphoglycoprotein (Pgp),
an efflux protein in cancer cells [20-22]. Multi-drug resis-
tance (MDR)-like proteins are involved in quinoline resis-
tance in P. falciparum [23-25]. PfMRP is involved in QN
resistance [26,27].
The objectives of this study were 1) to assess the in vitro
potentiation effects of AVA in combination with QN
against 21 strains of P. falciparum that were isolated from
a wide panel of countries and had different drug suscepti-
bility profiles, and 2) to evaluate if AVA could be an inhib-
itor of P. falciparum MDR -like proteins, such as P gh1,
PfMRP or PfMDR2, or transporters involved in drug
resistance, such as PfCRT (P. falciparum chloroquine
resistance transporter) [28] and PfNHE-1 (P. falciparum
sodium/hydrogen exchanger) [29,30].
Methods
Plasmodium falciparum cultures
Twenty-one parasite strains or clones from a wide panel
of countries (Brazil, Cambodia, Cameroon, Djibouti,
French Guyana, the Gambia, Honduras, Indochina,
Niger, Republic of Comoros, Republic of the Congo, Sen-
egal, Sierra Leone, Sudan, and Uganda) were maintained
in culture in RPMI 1640 (Invitrogen, Paisley, UK) supple-
mented with 10% human serum (Abcys S.A. Paris,
France) and buffered with 25 mM HEPES and 25 mM
NaHCO3. Parasites were grown in type A+ human red
blood cells under controlled atmospheric conditions (10%
O2, 5% CO2, and 85% N2) at 37°C with a humidity of 95%.
All strains were synchronized twice with sorbitol before
use [31]. Clonality was verified using PCR genotyping of
polymorphic genetic markers, msp1, msp2, and microsat-
ellite loci [32,33]. The potentiation evaluation for each
strain was assessed in three independent experiments.
Drugs
AVA calcium salt was purchased from Molekula (UK).
QN was purchased from Sigma (Saint Louis, MO). AVA
was dissolved in 1% DMSO (v/v) in RPMI. Two-fold serial
dilutions, with final concentrations ranging from 0.01 μM
to 200 μM, were prepared in 1% DMSO in RPMI and
plated in 96-well plates just before use. QN was dissolved
first in methanol and then diluted in water to obtain final
concentrations ranging from 5 to 3400 nM.
In vitro assay
In order to assess the synergy of AVA with QN, 25 μl of
AVA per well and 200 μl of the suspension of synchro-
nous parasitized red blood cells (final parasitaemia, 0.5%;
final haematocrit, 1.5%) per well were plated in 96-well
plates containing the QN concentrations. The in vitro
isotopic micro-test used had been previously described
[34].
The drug concentration able to inhibit 50% of parasite
growth (IC50) was calculated as the drug concentration
corresponding to 50% of the incorporation of tritiated
hypoxanthine by the parasite in the drug-free control
wells. The IC50 value was determined using the non-lin-
ear regression analysis of log-based dose-response curves
(Riasmart, Packard, Meriden, USA).Parquet et al. Malaria Journal 2010, 9:139
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In order to evaluate the modulation of QN resistance by
AVA, isobolograms were constructed by plotting a pair of
fractional IC50 for each combination of AVA and QN for
both parasite strains. The AVA fractional IC50 was calcu-
lated by dividing their fixed concentrations by the IC50 of
tested drugs alone and plotted on the horizontal axis. The
QN fractional IC50 was calculated by dividing the IC50 of
QN combined with fixed concentrations of AVA and
plotted on the vertical axis. Points lying above the diago-
nal line (corresponding to the points where there is no
interaction between the drugs) are antagonistic, points
below the diagonal line are considered to be synergistic.
The interaction parameter indicating relative degree of
interaction (I) was calculated using the equation Yi = 1-
[Xi/(Xi + ei
* (1 - Xi))], where Yi = IC50 for AVA when com-
bined with QN and Xi = IC50 for QN when combined with
AVA [35]. This representation of drug interaction pro-
vides a single quantitative estimate of relative degree of
interaction even when the experimental ratios are not
optimum. Positive values of I indicate synergism, negative
values antagonism; addition occurs when it equals zero.
In addition, three concentrations of AVA (0.1, 0.5 and 1
μM), which were relevant with A V A plasma concentra-
tions achievable in patients taking 80 mg of AVA daily
[36], were reanalysed separately. The concentration of
AVA that reduced the IC50 o f  Q N  b y  5 0 %  w h e n  u s e d
alone, [AVA]QN, was calculated for each strain of P. falci-
parum.
Nucleic acid extraction
The total genomic DNA of each strain was isolated using
the E.Z.N.A. Blood DNA kit (Omega Bio-Tek, GA,
U.S.A.). The RNA of each strain was purified using the
QIAamp Blood Mini kit (QIAGEN, Germany). The
methods for the SNPs identification of pfcrt [37], pfmdr1
[38], pfmdr2 [38] and pfmrp [38], for the identification of
pfnhe-1 microsatellite profiles [29,37] and for the estima-
tion of the copy number of pfmdr1 and pfmdr2 [38] were
previously described.
Statistical analysis
The differences in MQ IC50 between AVA concentrations
groups have first been tested using ANOVA for repeated
measures to take into account the fact that observations
made within each strain were not independent. Using the
most conservative correction for interdependence
between observations (i.e. Box's conservative epsilon),
the differences in QN IC50 were tested for concentrations
relevant with AVA plasma concentrations achievable in
patients taking 80 mg of AVA daily (0.1, 0.5 and 1 μM).
Using a random effect linear regression approach, the
regression coefficients for the log-transformed QN
IC50% indicated the significance of the mean fold change
in QN IC50 when adding AVA concentrations of 0.1, 0.5
and 1.0 μM.
The Kruskal-Wallis test or the Mann-Whitney U test of
was used, when appropriate, to compare the equality of
the populations for each mutation. The results of these
tests were compared according to the alleles at each
locus. The differences in IC50 for QN were then tested 22
times (i.e., one per locus). The probability of getting a sig-
nificant result with 22 tests at the α = 0.05 level of signifi-
cance was 1-0.9522  (1-probability of not getting a
significant result with 22 tests). According to the Bonfer-
roni correction, it was concluded that a difference was
significant when at least one of the 22 comparisons
yielded a significance level below 0.05/22 = 0.0023.
Results
Results of in vitro potentiation
AVA demonstrated synergistic effects in combination
with QN (Figure 1). The differences in QN IC50 between
AVA concentrations groups have first been tested using
ANOVA for repeated measures to take into account the
fact that observations made within each strain were not
independent. Using the most conservative correction for
interdependence between observations (i.e. Box's conser-
vative epsilon), the differences in QN IC50 were highly
significant (p < 0.009) at concentrations relevant with
AVA plasma concentrations achievable in patients taking
80 mg of AVA daily (Table 1). Using a random effect lin-
ear regression approach, the regression coefficients for
the log-transformed QN IC50% indicated that the mean
fold change in QN IC50 when adding AVA concentrations
of 0.1, 0.5 and 1.0 μM (0.95; 0.90 and 0.78, respectively)
Figure 1 In vitro synergistic interactions between atorvastatin 
(AVA) and quinine (QN) against the 21 strains of P. falciparum.
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were also highly significant (p < 0.009). The QN IC50 was
reduced by 5% (0% to 15%; 95%CI: 1%-8%), 10% (3% to
23%; 95%CI: 7%-14%) and 22% (14% to 40%; 95%CI: 19%-
25%) in presence of AVA at concentrations of 0.1, 0.5 and
1.0 μM, respectively. These reductions were all significant
(p < 0.009). Another finding was that the synergy of the
effects of QN was AVA dose-dependent. The reductions
in QN IC50 were also significant between 0.1 AVA and 0.5
AVA (p < 0.0014) and between 0.5 AVA and 1.0 AVA (p <
0.0001).
Eleven strains (53%) had interaction parameter indicat-
ing relative degree of interaction (I) > 1 (synergism) and 7
(33%) with 0 < I < 1 (weak synergism). Three strains (14%)
had I ranging from -1 to 0 (weak antagonism).
The concentrations of AVA that reduced the IC50 of QN
when used alone by 50% ([AVA]QN) ranged from 1.1 to
13.0 μM (geometric mean = 3.7 μM and 95% confidence
interval = 2.8-5.1). The reduction of the QN IC50 in pres-
ence of AVA was not significantly correlated with the QN
IC50 (r = 0.22, P = 0.3288) or the AVA IC50 (r = 0.03, P =
0.8946).
Genotypes and gene copy number of the 21 strains of P. 
falciparum
The following mutations were identified in at least one
strain:  pfcrt  M74I, N75E, K76T, A220S, Q271(E/V),
N326S, I356T, and I371R; pfmrp  H191Y and S437A;
pfmdr1 N86Y, Y184F, S1034C, N1042D, and D1246Y; and
pfmdr2 S208N and F423Y. Eight different ms4760 micro-
satellite profiles of pfnhe-1 were observed. The number of
DNNND and DDNHNDNHNN repeats in ms4760
ranged from one to four and one to two, respectively. The
copy number of pfmdr1 ranged from one to three. Only
one copy of pfmdr2 was found in all of the 21 P. falci-
parum strains.
Association of in vitro responses (IC50) and polymorphisms 
of genes
The association between polymorphism in pfcrt  gene
(codons 75, 76 and 220, P < 0.0022) or in pfmrp gene
(codons 191 and 437, P = 0.0008) and QN responses, used
alone, was highly significant (Additional file 1). The asso-
ciations between ms4760 profiles, number of DNNND
repeats or polymorphism in pfmdr1 gene (codons 1034
and 1042) and QN responses were not significant (P <
0.05 but > 0.0023) (Additional file 1). The synergistic
effect of AVA on QN responses was not significantly
associated with polymorphisms in the pfcrt,  pfmdr1,
pfmrp and pfnhe-1 genes (Additional file 1).
Association of in vitro responses (IC50) and gene copy 
number
The association between pfmdr1 copy number and QN
responses was not significant (P = 0.0086) (Additional file
1). The synergistic effect of AVA on QN responses was
not significantly associated with pfmdr1 copy number (P
= 0.0428) (Additional file 1).
Discussion
Atorvastatin (AVA), a 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase inhibitor, inhibited the in
vitro growth of P. falciparum at the micromolar range.
Whereas the generally agreed upon level of efficacy is in
the low to mid-nanomolar range, if the mechanism of
action of a novel anti-malarial compound was sufficiently
new and different than those of the commonly used anti-
malarial drugs, this compound would warrant further
study. Nevertheless, AVA, used alone at 20 mg/kg of body
weight, failed to prevent death from cerebral malaria or
to effect parasitaemia in infected mice [39,40].
A large amount of scientific effort is spent on elucidat-
ing the mechanisms underlying the resistance to anti-
Table 1: In vitro susceptibility of Plasmodium falciparum strains to atorvastatin alone (AVA), quinine alone (QN) and the 
combination of QN + AVA at concentrations of 0.1 μM, 0.5 μM and 1.0 μM.
Strains IC50 AVA
alone
IC50 QN
alone
IC50 QN
+ AVA 0.1 μM
IC50 QN
+ AVA 0.5 μM
IC50 QN
+ AVA 1.0 μM
IC50 geometric 
mean
7.24 μM 359 nM 341 nM 321 nM 280 nM
IC50 mean 95% CI 6.68-7.86 216-596 203-574 190-542 165-474
Average IC50 
diminution
5% 10% 22%
Average IC50 
diminution 95%CI
1%-8% 7%-14% 19%-25%
P-value (vs QN 
alone)
0.009 < 0.001 < 0.001
95%CI: 95% Confident IntervalParquet et al. Malaria Journal 2010, 9:139
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malarial drugs with the hope of restoring/improving the
efficacy of existing drugs and developing new drugs that
can bypass the resistance mechanisms. One of the strate-
gies that has been used to reduce the prevalence of
malaria is the use of drug combinations. The combina-
tion protects each drug from the development of resis-
tance and reduced the overall transmission rate of
malaria [41]. The absence of in vitro cross-resistance
between AVA and QN or the other anti-malarial drugs
suggested that AVA could be a good potential partner for
these anti-malarial drugs [18]. These different consider-
ations and the capacity of AVA to inhibit human Pgh [22]
lead us to evaluate AVA in combination with QN. AVA
potentiated the activity of QN against 86% of the P. falci-
parum  parasites tested (53% of synergism and 33% of
weak synergism). However, AVA did not improve the QN
responses of the totality of the strains tested. The potenti-
ation was independent of the QN susceptibility level.
AVA improved the in vitro activity of QN at concentra-
tions relevant with AVA plasma concentrations achiev-
a b l e  i n  p a t i e n t s  t a k i n g  8 0  m g  o f  A V A  d a i l y  [ 3 6 ] .
Furthermore, the administration doses of AVA in humans
could be increased to 120 mg daily with only limited
additional side effects [42]. A dose of 120 mg of AVA
increased the maximal plasma concentration of Cmax
after oral administration by levels from 4 to 10 fold. Cere-
bral malaria shares common pathophysiological features
with sepsis, especially with regard to the pathology of the
endothelium [43], and critically ill patients with sepsis
had a significantly higher Cmax when compared to the
healthy volunteers (110.5 vs. 5.9 ng/ml) [44]. The most
important adverse events related to the use of atorvasta-
tin are muscle toxicity and the effects on liver enzymes.
However, rhabdomyolysis and creatinine kinase or
transaminase level were not significantly increased in tri-
als of intensive statin therapy or at high dose of AVA (80
mg/day) for periods ranging from 2 weeks to 5 years and
were not age related [45-48]. The administration doses of
AVA in humans at 120 mg daily did not induce rhab-
domyolysis [42]. Cases of rhabdomyolysis were observed
when AVA was co-administrated with other drugs, such
as fusidic acid or ezetimibe or in patients with nephrotic
syndrome. Biochemical evidence of skeletal muscle dam-
age was common in malaria, but rhabdomyolysis
appeared to be rare [49-51]. Rhabdomyolysis should be
carefully survey in co-administration of AVA in malaria.
Nevertheless, these effects were not associated with
polymorphisms in the genes involved in QN resistance
such as pfcrt  [28,52],  pfmdr1  [53],  pfmrp  [26,54], or
pfnhe-1 [29,30,55]. The synergistic effect of AVA in com-
bination with QN was found to be unrelated to mutations
occurring in the transport protein genes involved in quin-
oline drug resistance. In addition, the synergistic effect of
AVA on QN responses was not significantly associated
with pfmdr1 copy number but, as QN resistance, the sig-
nificance level of this association was above the Bonfer-
roni-corrected P value threshold (0.0023) but below 0.05.
These data suggested that AVA could interfere with Pgh1,
as predicted by the inhibition of Pgh in human cells by
AVA [20-22]. However, this is a preliminary report.
Twenty-one strains may not be sufficient to make definite
conclusions.
Synergy of QN with AVA is a promising result in
malaria treatment. QN remains the first line anti-malarial
drug for the treatment of complicated malaria in Europe
and Africa. However, clinical failures became more fre-
quent in Southeast Asia, South America and Africa
[4,6,8]. Artemisinin-based combination therapy (ACT)
was proposed as a first-line treatment for uncomplicated
malaria six years ago. However, individual P. falciparum
isolates resistant to artemisinin in vitro and the first clini-
cal failures have been described in Cambodia [56-60].
This emergence of parasite resistance to ACT indicates
that novel compounds and combinations need to be dis-
covered and developed. These data suggest that AVA will
be a good candidate for combination with QN in malaria
treatment.
Conclusions
The mechanism underlying the anti-malarial activity of
AVA is currently unknown. The absence of cross-resis-
tance with QN, chloroquine, monodesethylamodiaquine,
mefloquine, lumefantrine, dihydroartemisinin, atova-
quone, or doxycycline suggests a different mechanism of
drug uptake and/or mode of action for AVA [18]. AVA is a
3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitor. Nevertheless, an HMG-CoA homolog was not
i d e n t i f i e d  b y  B L A S T X  a n a l y s i s  o f  t h e  P. falciparum
genome with other protozoal HMG-CoA proteins
sequences. Parasites treated with mevastatin demon-
strated depressed biosynthesis of dolichol and isoprenoid
pyrophosphate [61]. In addition, mevastatin decreased
the viability of cells through inhibition of the proteasome.
One of the future objectives is to identify modifications of
the  P. falciparum proteome in parasites treated with
AVA.
The different mechanisms of drug uptake and/or mode
of action for AVA compared to the other anti-malarial
drugs, as well as the A V A-mediated potentiation of the
anti-malarial effect of QN, suggests that AVA will be a
good candidate for combinatorial malaria treatment. All
of these observations support calls for both an in vivo
evaluation with pharmacokinetic component and clinical
trials of AVA as an anti-malarial therapy.
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